Compare EPSN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 154.9M |
| IPO Year | 2018 | 2002 |
| Metric | EPSN | KZIA |
|---|---|---|
| Price | $5.87 | $13.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 114.8K | ★ 197.4K |
| Earning Date | 05-13-2026 | 06-04-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $295.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $4.86 |
| 52 Week High | $6.65 | $17.40 |
| Indicator | EPSN | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 57.26 |
| Support Level | $5.57 | $11.32 |
| Resistance Level | $5.96 | $14.74 |
| Average True Range (ATR) | 0.21 | 1.14 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 77.59 | 72.01 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.